Pharmacists in Desloge, MO Accepting Medicare
10 Pharmacists found. Showing 1 - 10
 Lauren Williams, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1142 N Desloge Dr, Desloge, MO 63601 Phone: 573-431-2242 Fax: 573-431-4799 |
Angela Dawn Ibaviosa, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Parkland Health Mart 617 N. Cowling Ste G, Desloge, MO 63601 Phone: 573-431-6677 |
 Zachary Thomas Toenjes Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 407 N State St, Desloge, MO 63601 Phone: 618-581-4578 |
Dr. Cynthia Pikey, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 407 N State St, Desloge, MO 63601 Phone: 573-431-8563 |
Holly Russell Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 407 N State St, Desloge, MO 63601 Phone: 573-431-8563 |
Nicholas Joseph Dupont, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 407 N State St, Desloge, MO 63601 Phone: 573-431-8563 Fax: 573-431-7642 |
Dr. Amber Pashia, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 617 N Cowling St, Ste. G, Desloge, MO 63601 Phone: 573-431-6677 |
Dr. Cara Shepard-propst, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1142 N Desloge Dr, Desloge, MO 63601 Phone: 573-431-2242 Fax: 573-431-4799 |
Molly C Smith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1131 N Desloge Dr, Desloge, MO 63601 Phone: 573-431-6677 Fax: 573-431-3833 |
Rachel Anne Meredith, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1142 N Desloge Dr, Desloge, MO 63601 Phone: 573-431-2242 Fax: 573-431-4799 |
News Archive
Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).
Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
Food allergies in inner-city children: an interview with Dr. Robert Wood
The general interest is in trying to better define the true prevalence of food allergy; not just how common it is, but whether it's becoming more common over time.
Skin patch treatment kills common skin cancer
A skin patch treatment for basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.
Medication errors continue even in highly computerized hospital
Errors in drug ordering, dosage and monitoring that may have serious consequences for patients persist in hospitals even after the adoption of computerized medication systems, according to a study in the May 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 5 days ago
Occupational Therapists
Pharmacists
Counselors
Clinical Social Workers
Dentists